Literature DB >> 1936473

Glucose and lipid metabolism in non-insulin-dependent diabetes. Effect of metformin.

A Riccio1, S Del Prato, S Vigili de Kreutzenberg, A Tiengo.   

Abstract

Basal and insulin-mediated glucose and free-fatty acid (FFA) metabolism was evaluated in 6 non-insulin-dependent diabetic patients (NIDDM) previously treated by diet, before and after 4 week metformin treatment (850 mg twice/day). On both occasions, an euglycemic stepwise insulin (20 and 40 mU/m2/min) clamp was performed along with primed-continuous infusion of 3-3H-glucose and 1-14C-palmitate and indirect calorimetry monitoring. FFA oxidation rate was measured from the rate of appearance of 14CO2. After metformin therapy, fasting plasma glucose, FFA, triglyceride, total cholesterol concentrations and HbA1c were all lowered (p less than 0.05-0.01) in the absence of any change in plasma insulin levels. Plasma FFA turnover rate (5.3 +/- 0.5 vs 3.9 +/- 0.8 mumol/kg/min; p less than 0.05) and FFA oxidation (0.93 +/- 0.12 vs 0.70 +/- 0.12 mumol/kg/min; p less than 0.05) were also lower after metformin treatment, while glucose oxidation increased from 0.9 +/- 0.2 vs 1.2 +/- 0.1 mg/kg/min. During the insulin clamp studies, whole body glucose disposal was higher both at the lower (2.1 +/- 0.4 vs 2.8 +/- 0.4 mg/kg/min) and higher insulin plateau (4.8 +/- 0.9 vs 6.3 +/- 0.9 mg/kg/min; p less than 0.01). Since no difference was apparent in glucose oxidation, the increase in glucose disposal was entirely accounted for by an improvement in non-oxidative glucose metabolism. Euglycemic hyperinsulinemia was followed by a reduction in plasma FFA concentration turnover rate that remained the same before and after metformin therapy. In conclusion, metformin treatment induces an improvement in glucose metabolism both in the basal and insulin-stimulated state.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1936473

Source DB:  PubMed          Journal:  Diabete Metab        ISSN: 0338-1684


  10 in total

Review 1.  A risk-benefit assessment of metformin in type 2 diabetes mellitus.

Authors:  H C Howlett; C J Bailey
Journal:  Drug Saf       Date:  1999-06       Impact factor: 5.606

2.  Energy transfer in "parasitic" cancer metabolism: mitochondria are the powerhouse and Achilles' heel of tumor cells.

Authors:  Ubaldo E Martinez-Outschoorn; Richard G Pestell; Anthony Howell; Mark L Tykocinski; Fnu Nagajyothi; Fabiana S Machado; Herbert B Tanowitz; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2011-12-15       Impact factor: 4.534

Review 3.  The antihyperglycaemic effect of metformin: therapeutic and cellular mechanisms.

Authors:  N F Wiernsperger; C J Bailey
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 4.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Authors:  Shelley R Salpeter; Elizabeth Greyber; Gary A Pasternak; Edwin E Salpeter
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

5.  SPHK1 Is a Novel Target of Metformin in Ovarian Cancer.

Authors:  Peter C Hart; Tatsuyuki Chiyoda; Xiaojing Liu; Melanie Weigert; Marion Curtis; Chun-Yi Chiang; Rachel Loth; Ricardo Lastra; Stephanie M McGregor; Jason W Locasale; Ernst Lengyel; Iris L Romero
Journal:  Mol Cancer Res       Date:  2019-01-17       Impact factor: 5.852

6.  Is cancer a metabolic rebellion against host aging? In the quest for immortality, tumor cells try to save themselves by boosting mitochondrial metabolism.

Authors:  Adam Ertel; Aristotelis Tsirigos; Diana Whitaker-Menezes; Ruth C Birbe; Stephanos Pavlides; Ubaldo E Martinez-Outschoorn; Richard G Pestell; Anthony Howell; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2012-01-15       Impact factor: 4.534

Review 7.  Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus.

Authors:  C J Dunn; D H Peters
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

8.  Biguanides and thiazolidinediones inhibit stimulated lipolysis in human adipocytes through activation of AMP-activated protein kinase.

Authors:  O Bourron; M Daval; I Hainault; E Hajduch; J M Servant; J F Gautier; P Ferré; F Foufelle
Journal:  Diabetologia       Date:  2009-12-31       Impact factor: 10.122

9.  Importance of the intestine as a site of metformin-stimulated glucose utilization.

Authors:  C J Bailey; K J Mynett; T Page
Journal:  Br J Pharmacol       Date:  1994-06       Impact factor: 8.739

Review 10.  Altered energy metabolism in cancer: a unique opportunity for therapeutic intervention.

Authors:  Yi Zhang; Jin-Ming Yang
Journal:  Cancer Biol Ther       Date:  2012-11-28       Impact factor: 4.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.